Tag Archives: life science companies

Sentry Helps the DEA to Raise Public Awareness about the 11th National Prescription Drug Take-Back Day Initiative

As part of the U.S. Drug Enforcement Administration’s (DEA’s) National Prescription Drug Take-Back Day Initiative (NTBI), people will be able to dispose of expired, unwanted or unused prescription drugs on Saturday, April 30, 2016 from 10:00 a.m. to 2:00 p.m. at numerous collection sites around the U.S.

“The DEA’s program is designed to focus national attention on the proper disposal of prescription drugs and controlled substances,” said Ms. Jennifer Marcum, Sentry BioPharma Services’ chief executive officer.  Marcum continued, “During the event, people can bring their unwanted prescription pharmaceuticals and over-the-counter (OTC) medications to a participating drop-off site for proper drug disposal by law enforcement authorities with no questions asked.  The service is not only free and anonymous, but also an ideal way to preserve the environment from unwanted pharmaceutical contamination.  This is a terrific opportunity for those who missed the previous events, or who have subsequently accumulated unwanted, unused prescription drugs, to safely dispose of those medications.”

Americans that participated in the DEA’s tenth annual National Prescription Drug Take-Back Day on September 26, 2015, turned in more than 350 tons of unwanted or expired medications for safe and proper drug disposal at more than 5,000 take-back collections sites available in all 50 states and U.S. territories.  When the results of the ten prior Take-Back Days are combined, the DEA, and its state, local, and tribal law-enforcement and community partners have removed 5,525,021 pounds of drugs from circulation.

“The numbers are shocking—approximately 46,000 Americans die each year from drug-related deaths.  More than half of those are from heroin and prescription opioids,” said Acting DEA Administrator Chuck Rosenberg.  “With four out of five new heroin users starting with prescription medications, I know our take-back program makes a real difference.”  The NTBI addresses a crucial public safety and public health issue.  According to the 2014 National Survey on Drug Use and Health, 6.5 million Americans abused controlled prescription drugs.  That same study showed that a majority of abused prescription drugs are obtained from family and friends, including from the home medicine cabinet.  The DEA’s NTBI events are also a significant piece of the White House Office of National Drug Control Policy’s prescription drug abuse prevention strategy.

Sentry BioPharma Services will also continue its support of the DEA’s efforts by helping to raise public awareness of this important initiative.  For more information about the drug disposal program, general public inquiries can be made by calling the DEA toll free at: 1-800-882-9539.

Sentry BioPharma Services’ Employees Make a Declaration to Fight Breast Cancer

Did you know that one in eight women in the U.S. will be diagnosed with breast cancer in her lifetime?  At this current rate 13 million breast cancer deaths around the world will occur in the next 25 years.

While certain factors affect prognosis (chance of recovery) and treatment options, research on the biology of cancer is necessary to answer the most basic questions about what is and what is not normal.  The outcomes of basic research in cancer biology are often uncertain, which makes oncology funding from profit-driven sources a risky undertaking.

On December 19, 2015 the National Institutes of Health (NIH) received a nearly $2 billion increase in funding for FY16 by way of approval of the Omnibus Appropriations Bill.  The bill provided for continued funding for the Department of Defense’s Breast Cancer Research Program.   Despite the increase, the National Cancer Institute’s (NCI’s) budget falls $238 million short of the $5.5 billion the institute requested for the fiscal year 2017 budget.  Federal funding helps but is simply not enough to develop the arsenal of tools and strategies needed for sharing and communicating about oncology research results.  More help is needed to fight this battle!

Amber M. Reed, Sentry BioPharma Services’ Warehouse Supervisor, declares her commitment to be a “Pink Warrior” by participating in the 25th Anniversary Komen Central Indiana Race for the Cure® on Saturday, April 16, 2016 commencing at the historic Military Park in downtown Indianapolis, Indiana.  Ms. Reed says, “I have lost my grandmother and great-grandmother to breast cancer. My grandmother was like a mother to me. Since her passing in 2006 I have pledged to do whatever I can to help in the research to find a cure for this awful disease. I have participated in either Relay for Life® or Race for the Cure® every year since. I love the fact that I work for a company that also shares my dedication in helping to find a cure for cancer. Together I believe we can make cancer a thing of the past.”

According to the race sponsor’s website, “the Susan G. Komen Race for the Cure® Series is the world’s largest and most successful education and fundraising event for breast cancer ever created.  The event raises significant funds and awareness for the breast cancer movement, celebrates breast cancer survivorship and honors those who have lost their battle with the disease.

This race is unique in the fact that 100% of the net proceeds are allocated to our mission. Seventy-five percent of the net income stays in our community to help fund local programs offering breast health education and breast cancer screening and treatment. The remaining 25% of the net income supports the Susan G. Komen® Grants Program.

Sentry BioPharma Services supports Ms. Reed’s efforts and commits to helping raise public awareness of this important cause.  The company pledges on-going help to vaccine manufacturers by offering reliable GMP warehousing and drug distribution services to eliminate variables in oncology clinical trials in hope of one day eradicating this deadly disease.

 

Warehouse Coordinator Chris Harris and Chief Operations Officer Dwayne Marcum

Warehouse Coordinator Chris Harris and Chief Operations Officer Dwayne Marcum

IMG_0056

Left to right: Warehouse Supervisor Amber Reed, Inside Sales Representative Jasmine Enlow, Chief Executive Officer Jennifer Marcum, Warehouse Coordinator Chris Harris

IMG_0614

Sentry BioPharma Services Confirms Attendance at BIO 2016 in San Francisco, California

Sentry BioPharma Services returns to the birthplace of biotech, San Francisco, California in June 2016. This marks Sentry’s 11th consecutive year attending the Biotechnology Innovation Organization’s (BIO’s) International Convention. Sentry leadership selects this conference annually primarily because it attracts over 15,000 biotechnology and pharma representatives from all over the world who unite for one week in the U.S. The topics discussed during this event and in the exhibit hall cover a wide spectrum of relevant life science topics as well as areas like drug discovery, GMP compliance, bio-manufacturing, genomics and cell therapy.

“BIO One-on-One Partnering™ serves as a cost effective way to interact globally without the extensive international traveling requirements” states Sentry’s President, Tim J. Mitchell. “There are 3,100+ companies participating in these meetings. We find the online scheduling tool to be exceptionally user-friendly and effective which allows us to interact with a vast number of prospective pharmaceutical partners and companies developing biological products. We efficiently present information concerning our customized pharmaceutical labeling, packaging and kitting processes. We also entertain numerous questions concerning Sentry’s international drug distribution services in the pavilions and/or at booths in the exhibit hall, all within the allotted 25-minute time frame. It’s amazing what can be accomplished in 3 1/2 days at BIO!”

The BIO One-in-One Partnering™ feature allows Sentry’s leaders to network and discover new opportunities and potential partnerships. Please meet us at the 2016 BIO International Convention in San Francisco, USA.

Contact Sentry via email or by phone at 1-866-757-7400.

https://convention.bio.org/2016/